StoxAjanta Pharmaceuticals vs Sai Life Sciences: share price & financials comparison
NSE: AJANTPHARM vs SAILIFE · Healthcare · as of 06 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Ajanta Pharmaceuticals vs Sai Life Sciences at a glance
Ajanta Pharmaceuticals (AJANTPHARM) has a market capitalisation of ₹41,462 Cr, against ₹37,919 Cr for Sai Life Sciences (SAILIFE). Over the past year Sai Life Sciences has returned +94.7%, compared with +34.4% for Ajanta Pharmaceuticals. On valuation, Ajanta Pharmaceuticals trades at a lower P/E of 32.9 versus 187.2. Ajanta Pharmaceuticals earns a higher return on equity (25.9% vs 7.5%). Ajanta Pharmaceuticals comes out ahead on size, valuation, profitability, growth and financial health. Sai Life Sciences comes out ahead on momentum and technicals. Across the scored metrics below, Ajanta Pharmaceuticals leads on 7 and Sai Life Sciences on 5. On StoxGud's 10-point checklist, Ajanta Pharmaceuticals scores 9/10 and Sai Life Sciences scores 6/10.
| Metric | Ajanta Pharmaceuticals | Sai Life Sciences |
|---|---|---|
| Size | ||
| Market cap | ₹41,462 Cr | ₹37,919 Cr |
| Revenue (latest FY) | ₹5,453 Cr | ₹2,192 Cr |
| Net profit (latest FY) | ₹1,056 Cr | ₹349 Cr |
| Valuation | ||
| P/E | 32.9 | 187.2 |
| P/B | 8.53 | 14.11 |
| Dividend yield | 0.84% | — |
| Profitability | ||
| Return on equity | 25.9% | 7.5% |
| Net profit margin | 20.2% | 8.5% |
| Operating margin | 27.1% | 29.5% |
| Growth | ||
| Revenue growth (YoY) | +32.5% | +22.5% |
| Net profit growth (YoY) | +49.2% | — |
| Revenue CAGR (multi-year) | +13.5% | — |
| Financial health | ||
| Debt to equity | 0.02 | 0.17 |
| Momentum | ||
| 1-month return | -7.3% | +14.3% |
| 1-year return | +34.4% | +94.7% |
| 3-year CAGR | +22.1% | — |
| 5-year CAGR | +17.9% | — |
| 10-year CAGR | +10.0% | — |
| Distance from 52W high | -11.0% | +0.0% |
| Technicals | ||
| RSI (14) | 48 | 93 |
| Price vs 200-day avg | +4.1% | +47.1% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Ajanta Pharmaceuticals | Sai Life Sciences |
|---|---|---|
| Price above 50-day average | ✗ | ✓ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✓ | ✓ |
| RSI in healthy 40–70 zone | ✓ | ✗ |
| Positive 1-year return | ✓ | ✓ |
| Return on equity above 15% | ✓ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✓ | ✗ |
| P/E below industry median | ✓ | ✗ |
| Score | 9/10 | 6/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Ajanta Pharmaceuticals or Sai Life Sciences?
Ajanta Pharmaceuticals has a market cap of ₹41,462 Cr and Sai Life Sciences has a market cap of ₹37,919 Cr as of 06 Nov 2026.
Which has a lower P/E, Ajanta Pharmaceuticals or Sai Life Sciences?
Ajanta Pharmaceuticals has the lower P/E: Ajanta Pharmaceuticals trades at 32.9 and Sai Life Sciences at 187.2.
Which gave better returns in the last year, Ajanta Pharmaceuticals or Sai Life Sciences?
Sai Life Sciences did better: Ajanta Pharmaceuticals returned +34.4% and Sai Life Sciences returned +94.7% over one year.
Is Ajanta Pharmaceuticals or Sai Life Sciences a better buy?
StoxGud does not give buy or sell recommendations. On our rules-based checklist Ajanta Pharmaceuticals scores 9/10 and Sai Life Sciences scores 6/10; compare valuation, profitability, growth and momentum above and consult a SEBI-registered adviser.